Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease worldwide and is characterized by insulin resistance, hepatic steatosis and often prediabetes or diabetes. Canagliflozin, a selective sodium glucose cotransporter 2 inhibitor, is a new oral anti‐diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Itani, Toshio, Ishihara, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180715/
https://www.ncbi.nlm.nih.gov/pubmed/30338118
http://dx.doi.org/10.1002/osp4.294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180715/
https://www.ncbi.nlm.nih.gov/pubmed/30338118
http://dx.doi.org/10.1002/osp4.294

Ejemplares similares